Zaleplon

CNS Drugs

Volumn 11, Issue 5, 1999, Pages 387-392

  Hurst, Miriam ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR; FLURAZEPAM; PLACEBO; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AREA UNDER THE CURVE; ARTICLE; DRIVING ABILITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; MEMORY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY;

EID: 0032958699     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911050-00006     Document Type: Article

References (23)

1. 1. Becker PM, Jamieson AO, Brown WD. Insomnia. Use of a decision tree to assess and treat. Postgrad Med 1993 Jan; 93 (1): 66-80, 85
2. 2. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998 Jun; 32: 680-91
3. 3. Kupfer DJ, Reynolds CF III. Management of insomnia. N Engl J Med 1997 Jan 30; 336: 341-6
4. 4. Beer B, Clody DE, Mangano R, et al. A review of the preclinical development of zaleplon, a novel non-benzodiazepine hypnotic for the treatment of insomnia. CNS Drug Rev 1997; 3 (3): 207-24
5. 5. Sanger DJ. Behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol 1995; 6 (2): 116-26
6. 6. Vanover KE, Barrett JE. Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846. Psychopharmacology 1994 Jul; 115: 289-96
7. 7. Walsh JK, Fry J, Erwin CW, et al. Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia. Clin Drug Invest 1998 Nov; 16 (5): 347-54
8. 8. Dietrich B, Farr I. Zaleplon: dose-response evaluation in primary insomnia [abstract]. Sleep Res 1995; 24A: 116
9. 9. Walsh JK, Pollack CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Philadelphia (PA): Wyeth-Ayerst Research, 1998. (Data on file)
10. 10. Dietrich B, Emilien G, Salinas E. Efficacy of zaleplon on sleep and daytime performance in a phase-advanced sleep model. Philadelphia (PA): Wyeth-Ayerst Research, 1998. (Data on file)
11. 11. Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. Philadelphia (PA): Wyeth-Ayerst Research, 1998. (Data on file)
12. 12. Ware JC, Allen R, Scharf MB, et al. An evaluation of residual sedation following nighttime administration of 10 or 20 mg of zaleplon, 30 mg of flurazepam, or placebo in healthy subjects [abstract no. 313.C]. Sleep 1998; 21 Suppl.: 263
13. 13. Vermeeren A, Danjou PE, O'Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharm 1998 Nov; 13 Suppl. 2: 98-107
14. 14. Rosen AS, Fournié P, Darwish M, et al. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 1999. In press
15. 15. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998 Nov; 64 (5): 553-61
16. 16. Lee W-H, Amorusi P, DeMaio W, et al. Metabolic disposition of radiolabeled zaleplon (CL-284,846) in healthy male volunteers. Philadelphia (PA): Wyeth-Ayerst Research, 1998. (Data on file)
17. 17. Beer B, Ieni JR, Wu W-H, et al. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J Clin Pharmacol 1994; 34: 335-44
18. 18. Vanover KE, Mangano RM, Barrett JE. CL 284,846, a novel sedative-hypnotic: evaluation of its metabolites for pharmacological activity in vitro and in vivo. Drug Dev Res 1994 Sep; 33: 39-45
19. 19. Darwish M, Martin PT, Cevallos WH, et al. Rapid disappearance of zaleplon from breast milk after oral administration to lactating women. J Clin Pharmacol 1999. In press
20. 20. Elie R, Davignon M, Emilien G. Zaleplon decreases sleep latency in outpatients without producing rebound insomnia after 4 weeks of treatment [abstract no. 151]. J Sleep Res 1998; 7 (2 Suppl.): 76
21. 21. Hedner J, Emilien G, Salinas E. Improvement in sleep latency and sleep quality with zaleplon in elderly patients with primary insomnia [abstract no. 229]. J Sleep Res 1998; 7 (2 Suppl.): 115
22. 22. Fry J, Scharf MB, Berkowitz DV, et al. A phase III, 28 day, multicenter, randomized, double-blind comparator-and placebo-controlled, parallel-group safety, tolerability, and efficacy study of 5, 10, and 20 mg of zaleplon, compared with 10 mg of zolpidem or placebo, in adult outpatients with insomnia [abstract no. 312.C]. Sleep 1998; 21 Suppl.: 262
23. 23. Rush CR, Frey JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology 1999. In press